2-chloro-10-methyl-8,9-dihydropyrido[1,2-a]indol-6(7H)-one | 129300-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-chloro-10-methyl-8,9-dihydropyrido[1,2-a]indol-6(7H)-one
• 英文别名: 2-chloro-8,9-dihydro-10-methylpyrido[1,2-a]indol-6(7H)-one；2-chloro-10-methyl-8,9-dihydro-7H-pyrido[1,2-a]indol-6-one
• CAS: 129300-50-1
• 化学式: C₁₃H₁₂ClNO
• 分子量: 233.697
• InChiKey: RBHAVUZPAHYXLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloro-10-methyl-8,9-dihydropyrido[1,2-a]indol-6(7H)-one 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以77 %的产率得到2-chloro-10-methyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-6-ol
  参考文献：
  名称：

  Development of a Non‐Directed Petasis‐Type Reaction by an Aromaticity‐Disrupting Strategy

  摘要：

  AbstractThe Petasis‐type reaction, which couples an imine and boronic acid, is an important tool for C−C bond formation in organic synthesis. However, the generality of this transformation has been limited by the requirement for a directing heteroatom to enable reactivity. Herein, we report the development of a non‐directed Petasis‐type reaction that allows for the coupling of trifluoroborate salts with α‐hydroxyindoles. By disrupting aromaticity to generate a reactive iminium ion, in conjunction with using trifluoroborate nucleophiles, the method generates a new C−C bond without the need for a directing group. This reaction is operationally simple, providing α‐functionalized indoles in up to 99 % yield using sp, sp2, and sp3‐hybridized trifluoroborate nucleophiles. Finally, this reaction is applied as a novel bioconjugation strategy to link biologically active molecules and toward the convergent synthesis of non‐natural heterodimeric bisindole alkaloid analogs.

  DOI：

  10.1002/anie.202218921
• 作为产物：
  描述：

  3-((4-chloro-2-iodophenyl)amino)-2-methylcyclohex-2-enone 在 potassium phosphate 、 palladium diacetate 作用下， 以 二甲基亚砜 为溶剂， 以74%的产率得到2-chloro-10-methyl-8,9-dihydropyrido[1,2-a]indol-6(7H)-one
  参考文献：
  名称：

  无配位钯催化环化/酰基迁移反应合成N稠合的多环吲哚

  摘要：

  描述了通过钯催化的环化/酰基迁移级联反应的N-稠合多环吲哚的有效合成。该反应是无配体的，可扩展的，并提供了从容易获得的起始原料获得各种有用的吲哚支架的途径。支持性的机理研究表明，该反应可能通过分子内α-芳基化机制进行。该方案的合成效用通过克级反应证明，并且可以合成吲哚生物碱和HSP90抑制剂。

  DOI：

  10.1021/acs.orglett.8b04128

文献信息

• Synthesis of <i>N</i>-Fused Polycyclic Indoles via Ligand-Free Palladium-Catalyzed Annulation/Acyl Migration Reaction
  作者：Zhan Dong、Xiao-Wen Zhang、Weishuang Li、Zi-Meng Li、Wen-Yan Wang、Yan Zhang、Wei Liu、Wen-Bo Liu

  DOI：10.1021/acs.orglett.8b04128

  日期：2019.2.15

  An efficient synthesis of N-fused polycyclic indoles by a palladium-catalyzed annulation/acyl migration cascade reaction is described. The reaction is ligand-free, scalable, and provides access to a diverse range of useful indole scaffolds from readily available starting materials. Supporting mechanistic studies indicate that the reaction likely proceeds via an intramolecular α-arylation mechanism

  描述了通过钯催化的环化/酰基迁移级联反应的N-稠合多环吲哚的有效合成。该反应是无配体的，可扩展的，并提供了从容易获得的起始原料获得各种有用的吲哚支架的途径。支持性的机理研究表明，该反应可能通过分子内α-芳基化机制进行。该方案的合成效用通过克级反应证明，并且可以合成吲哚生物碱和HSP90抑制剂。
• New 5-HT3(Serotonin-3) Receptor Antagonists. I. Synthesis and Structure-Activity Relationships of Pyrido(1,2-a)indoles.
  作者：Masayuki KATO、Kiyotaka ITO、Shigetaka NISHINO、Hisashi YAMAKUNI、Hisashi TAKASUGI

  DOI：10.1248/cpb.42.2546

  日期：——

  A series of pyrido[1,2-alpha]indol-6(7-H)-ones was prepared and evaluated for 5-HT3 receptor antagonist activity. The structural requirements for the 5-HT3 receptor antagonist have been defined as an aromatic moiety, a basic nitrogen, and a linking acyl group. The (5-methylimidazol-4-yl)methyl group as a basic nitrogen moiety was an important element for high potency. The highest potency was observed

  制备了一系列的吡啶并1,2-α吲哚-6（7-H）-酮，并评估了5-HT 3受体拮抗剂的活性。5-HT 3受体拮抗剂的结构要求定义为芳族部分，碱性氮和连接酰基。作为碱性氮部分的（5-甲基咪唑-4-基）甲基是高效力的重要元素。对于在吡啶并[1,2-α-吲哚-6（7H）-环上具有7-和10-甲基取代基的化合物，观察到最高的效力。从该系列中，选择（+）-11b（FK 1052）进行进一步评估。FK 1052在大鼠的Bezold-Jarisch反射试验中是有效的5-HT3受体拮抗剂（ED50 0.9微克/千克，静脉注射），并且是一种非常有效的止吐剂，可抵抗狗的顺铂引起的呕吐（ED50 1.2 x 2微克/千克， iv和2.7 x 2毫克/千克，口服）。
• Therapeutic agent for ischemic diseases
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05290785A1

  公开（公告）日：1994-03-01

  The invention relates to a method of treating cardiac ischemic disease using a compound of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, lower alkenyl or N,N-di(lower)alkylaminomethyl, R.sup.2 is hydrogen, lower alkyl or halogen, R.sup.3 is imidazolyl or pyridyl, each of which may have substituent(s) selected from lower alkyl and imino-protective group, and R.sup.4 is hydrogen, lower alkyl, lower alkenyl or hydroxy(lower)alkyl and R.sup.5 is hydrogen, hydroxy or lower alkanoyloxy, or R.sup.4 and R.sup.5 are linked together to form an additional bond, or a pharmaceutically acceptable salt thereof.

  本发明涉及使用式化合物治疗心肌缺血性疾病的方法：##STR1## 其中R.sup.1是氢、低碳基、低烯基或N，N-二(低)烷基氨甲基，R.sup.2是氢、低碳基或卤素，R.sup.3是咪唑基或吡啶基，每个基可能具有来自低碳基和亚氨基保护基的取代基，而R.sup.4是氢、低碳基、低烯基或羟基(低)烷基，R.sup.5是氢、羟基或低烷酰氧基，或R.sup.4和R.sup.5被连接在一起形成额外的键，或其药学上可接受的盐。
• Pyridoindole derivatives and processes for preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0361317B1

  公开（公告）日：1995-04-05
• Use of pyridoindole derivatives in the treatment of ischemic disorders
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0451538B1

  公开（公告）日：1996-05-22